"Large global brands realise there is a generic dislike of super brands, so they often like to appear smaller than they are to avoid negative publicity, " says Stuart Roper, a corporate reputation expert at Manchester Business School.
They are tied to greater needs such as the need for a global drug patent database to facilitate access to safe, cheap generic drugs that would help to undercut the black market.